Viz.ai as pharma demand layer

This turns Viz.ai from a hospital software vendor into a demand generation layer for drug makers. The core asset is not just the stroke or oncology workflow itself, it is the ability to spot eligible patients inside live clinical workflows, route that signal to care teams, and help pharma partners reach diagnosis and treatment decisions earlier. That creates a buyer beyond hospitals, because pharma can pay for faster therapy adoption across Viz.ai’s installed base.1 2 3 4 5

• Hospital subscriptions sell software to providers. The life sciences business sells access to patient finding and care pathway activation. In practice, Viz.ai flags likely COPD or cancer patients from imaging and clinical data, then pushes follow up tasks to clinicians, which gives pharma a concrete way to improve launch execution and patient start rates.1 2 4
• The partnerships show the model is becoming disease specific rather than generic. Sanofi and Regeneron use Viz.ai for COPD workflows. Novartis uses Viz Oncology for prostate and breast cancer. That means pharma is not buying broad brand awareness, it is buying a workflow tied to a therapy area where missed patients are common and time to treatment matters.1 3 4
• The Salesforce connector expands distribution beyond Viz.ai’s own interface. It lets real time clinical triggers flow into Agentforce Life Sciences and Data 360, where commercial, medical, and patient support teams already work. That makes Viz.ai more valuable to pharma because the alert can feed outreach, field activity, and support programs instead of stopping at the hospital wall.2 5

The next step is a broader shift from single hospital contracts to network monetization. As Viz.ai adds more disease modules and more pharma partners across its nearly 2,000 hospital footprint, the business can compound, because each new workflow makes the installed network more valuable to both providers and life sciences companies.1 2 5